|
rs80357086
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Conclusions:</b> A high proportion of Japanese HBOC patients showed the <i>BRCA1</i> L63X mutation, and the clinical characteristics of breast cancer in patients with this mutation might differ from those in patients with other <i>BRCA1</i> or <i>BRCA2</i> mutations, in terms of the subtype and nuclear grade of the resultant cancer.
|
31143373 |
2019 |
|
rs4149056
|
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
<b>Patients & methods:</b> Postmenopausal women with hormone-receptor positive breast cancer were genotyped for <i>SLCO1B1*5</i> (rs4149056) and rs10841753.
|
31190621 |
2019 |
|
rs10841753
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Patients & methods:</b> Postmenopausal women with hormone-receptor positive breast cancer were genotyped for <i>SLCO1B1*5</i> (rs4149056) and rs10841753.
|
31190621 |
2019 |
|
rs13047478
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>C21orf58</i> and <i>ZNF526</i> possessed functional roles in the control of breast cancer cell growth, and the two coding variants were found to be the eQTL for several nearby genes. rs13047478 was significantly (<i>P</i> < 5.00 × 10<sup>-8</sup>) associated with the expression of genes <i>MCM3AP</i> and <i>YBEY</i> in breast mammary tissues. rs3810151 was found to be significantly associated with the expression of genes <i>PAFAH1B3</i> (<i>P</i> = 8.39 × 10<sup>-8</sup>) and <i>CNFN</i> (<i>P</i> = 3.77 × 10<sup>-4</sup>) in human blood samples.
|
29572226 |
2018 |
|
rs3810151
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>C21orf58</i> and <i>ZNF526</i> possessed functional roles in the control of breast cancer cell growth, and the two coding variants were found to be the eQTL for several nearby genes. rs13047478 was significantly (<i>P</i> < 5.00 × 10<sup>-8</sup>) associated with the expression of genes <i>MCM3AP</i> and <i>YBEY</i> in breast mammary tissues. rs3810151 was found to be significantly associated with the expression of genes <i>PAFAH1B3</i> (<i>P</i> = 8.39 × 10<sup>-8</sup>) and <i>CNFN</i> (<i>P</i> = 3.77 × 10<sup>-4</sup>) in human blood samples.
|
29572226 |
2018 |
|
rs2228611
|
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
<i>DNMT1</i> rs2228611 may represent a determinant of radiation-induced fibrosis in breast cancer patients with promise for clinical usefulness in genetic-based predictive models.
|
27554481 |
2017 |
|
rs12670401
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>EZH2</i> rs12670401, <i>EZH2</i> rs6464926, age of menarche, and menopausal status were associated with breast cancer susceptibility.
|
29089464 |
2018 |
|
rs6464926
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>EZH2</i> rs12670401, <i>EZH2</i> rs6464926, age of menarche, and menopausal status were associated with breast cancer susceptibility.
|
29089464 |
2018 |
|
rs767151455
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>XRCC1</i> rs1799782 (C194T) polymorphism correlated with tumor metastasis and molecular subtypes in breast cancer.
|
30568466 |
2018 |
|
rs2273535
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
(ii) Haplotype analyses, based on different combinations of multiple SNPs in Aurora-A, revealed a strong association with breast cancer risk; interestingly, the genotypic distribution of the suggested functional Phe31Ile SNP was not significantly different between breast cancer patients and controls, but the specific haplotype containing the putative at-risk Ile allele was more common in patients.
|
15688402 |
2005 |
|
rs13281615
|
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
2008, this is the second study to confirm the association of 8q24.21-rs13281615 with breast cancer outcomes.
|
23717390 |
2013 |
|
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
550 samples (275 cases/275 control) of peripheral blood obtained from women (aged 22-87 years) with breast cancer and from healthy women (aged 23-87 years) were genotyped for frequencies of the following gene variances: R72P/rs1042522 (gene TP53) and S31R/ss4388499 (gene p21).
|
20127253 |
2010 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
550 samples (275 cases/275 control) of peripheral blood obtained from women (aged 22-87 years) with breast cancer and from healthy women (aged 23-87 years) were genotyped for frequencies of the following gene variances: R72P/rs1042522 (gene TP53) and S31R/ss4388499 (gene p21).
|
20127253 |
2010 |
|
rs1131691014
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
550 samples (275 cases/275 control) of peripheral blood obtained from women (aged 22-87 years) with breast cancer and from healthy women (aged 23-87 years) were genotyped for frequencies of the following gene variances: R72P/rs1042522 (gene TP53) and S31R/ss4388499 (gene p21).
|
20127253 |
2010 |
|
rs886039484
|
|
Breast Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
550 samples (275 cases/275 control) of peripheral blood obtained from women (aged 22-87 years) with breast cancer and from healthy women (aged 23-87 years) were genotyped for frequencies of the following gene variances: R72P/rs1042522 (gene TP53) and S31R/ss4388499 (gene p21).
|
20127253 |
2010 |
|
rs1057520001
|
|
Breast Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
550 samples (275 cases/275 control) of peripheral blood obtained from women (aged 22-87 years) with breast cancer and from healthy women (aged 23-87 years) were genotyped for frequencies of the following gene variances: R72P/rs1042522 (gene TP53) and S31R/ss4388499 (gene p21).
|
20127253 |
2010 |
|
rs10510102
|
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
9 of the remaining 37 were associated with breast cancer risk in young women with a p-value <0.05: rs10510102, rs1219648, rs13387042, rs1876206, rs2936870, rs2981579, rs3734805, rs3803662 and rs4973768.
|
31125336 |
2019 |
|
rs4973768
|
|
Breast Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
9 of the remaining 37 were associated with breast cancer risk in young women with a p-value <0.05: rs10510102, rs1219648, rs13387042, rs1876206, rs2936870, rs2981579, rs3734805, rs3803662 and rs4973768.
|
31125336 |
2019 |
|
rs2273535
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Breast cancer risk associated with AURKA 91T -->A polymorphism in relation to BRCA mutations.
|
17113223 |
2007 |
|
rs369982706
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Breast cancer risk associated with AURKA 91T -->A polymorphism in relation to BRCA mutations.
|
17113223 |
2007 |
|
rs372080166
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.
|
19526339 |
2010 |
|
rs200595749
|
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
A mutation in FYVE-CENT (R1945Q) associated with br</span>east cancer abolished the interaction between FYVE-CENT and Beclin 1, and reduced the localization of these proteins at the intercellular bridge during cytokinesis.
|
21455500 |
2011 |
|
rs3736316
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Breast cancer risk associated with duration of combined therapy was significantly modified by SRD5A1_rs3736316, showing a reduced risk elevation in carriers of the minor allele (p (interaction,empirical-Bayes) = 0.006 using the empirical-Bayes method, p (interaction,logistic regression) = 0.013 using logistic regression).
|
21947678 |
2012 |
|
rs36053993
|
|
Breast Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Breast cancer cases had a 6.7% prevalence of G396D, yielding a significantly elevated risk estimate for breast cancer (odds ratio, 1.86; 95% confidence interval, 1.02-3.39; P = .039).
|
21952991 |
2012 |
|
rs2228480
|
|
Breast Carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
Breast cancer risk was significantly associated with three SNPs located at 6q25.1-rs9383935 in CCDC170 and rs2228480 and rs3798758 in ESR1-with variant allele attributed odds ratios (ORs) of 1.38 (95% confidence interval (CI): 1.20 to 1.57, P=2.21×10(-6)), 0.84 (95% CI: 0.72 to 0.98, P=0.025) and 1.19 (95% CI: 1.04 to 1.37, P=0.013), respectively.
|
25116933 |
2014 |